CytomX Therapeutics (CTMX) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Monopar Therapeutics (MNPR) has outperformed CytomX Therapeutics (CTMX) over the past year, losing 15.0% versus a loss of 23.4%. Over five years, MNPR leads with a +241.3% price change compared with -50.4% for CTMX. Monopar Therapeutics is the larger company by market cap ($562.3 million vs $555.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTMX | MNPR |
|---|---|---|
| Share price | $2.55 | $83.78 |
| Market cap | $555.64M | $562.35M |
| 1-day change | -0.39% | +5.29% |
| YTD return | -40.14% | +28.30% |
| 1-year return | -23.42% | -14.96% |
| 5-year return | -50.39% | +241.26% |
| EPS (TTM) | $-0.51 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.21 | $124.82 |
| 52-week low | $2.48 | $50.07 |
| Distance from 52-week high | -68.94% | -32.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +380.39% | +55.07% |
| Average volume | 3.36M | 218.50K |
| Shares outstanding | 217.90M | 6.71M |
| Employees | 69 | 22 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Healthcare · Biotechnology · 69 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Healthcare · Biotechnology · 22 employees
CTMX vs MNPR FAQ
Which is bigger, CytomX Therapeutics or Monopar Therapeutics?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $562.35M compared with $555.64M for CytomX Therapeutics (CTMX).
Which stock has performed better over the past year, CTMX or MNPR?
MNPR returned -14.96% over the past 12 months, compared with -23.42% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are CytomX Therapeutics and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.